Alternatively, in the presence of H3.3-G34 oncohistone mutations, along with TP53 and ATRX loss of function (LOF) and PDGFRA gain of function (GOF), H3.3-G34-mutant gliomas develop. Here, PDGFRA is linked to central nervous system cancer.